Walker H, Singer C R, Patterson J, Goldstone A H, Prentice H G
Br J Haematol. 1986 Feb;62(2):385-91. doi: 10.1111/j.1365-2141.1986.tb02942.x.
Bone marrow from 39 patients who received a bone marrow transplant (BMT) from a matched donor of different sex were studied by chromosome analysis for evidence of mixed haemopoietic chimaerism (MC). Recipient metaphases were detected in the bone marrow of 10 patients after BMT. Patients in whom MC was detected within 6 weeks of BMT did not all have a poor outcome. Two of seven are disease-free survivors at greater than 470 and greater than 632 d. All three patients in whom MC was diagnosed more than 6 weeks after BMT subsequently relapsed. Four factors appear to be important in determining the probability of relapse when MC is detected in a patient after BMT: the timing of detection of residual recipient cells; the proportion of these cells in the bone marrow; persistence of these cells in increasing proportions; and the karyotype of the recipient metaphases detected. Cytogenetic assessment may provide the earliest indication of relapse in these patients. In addition, this study provides further evidence that cyclophosphamide and total body irradiation, as used in these patients, may be inadequate conditioning therapy for BMT.
对39例接受来自不同性别的匹配供体进行骨髓移植（BMT）的患者的骨髓进行染色体分析，以寻找混合造血嵌合体（MC）的证据。BMT后在10例患者的骨髓中检测到受者中期细胞。在BMT后6周内检测到MC的患者并非都预后不良。7例中有2例在超过470天和超过632天时无病存活。BMT后6周以上诊断出MC的所有3例患者随后均复发。当在BMT后的患者中检测到MC时，有四个因素在确定复发概率方面似乎很重要：残留受者细胞的检测时间；这些细胞在骨髓中的比例；这些细胞以增加的比例持续存在；以及检测到的受者中期细胞的核型。细胞遗传学评估可能为这些患者复发提供最早的迹象。此外，本研究进一步证明，这些患者中使用的环磷酰胺和全身照射可能作为BMT的预处理疗法并不充分。
